Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer

Journal of Clinical Oncology

Volumn 14, Issue 3, 1996, Pages 783-791

  Kennedy, M J ^a   Zahurak, M L ^a   Donehower, R C ^a   Noe, D A ^a   Sartorius, S ^a   Chen, T L ^a   Bowling, K ^a   Rowinsky, E K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM ALLOWABLE CONCENTRATION; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0029976216     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.3.783     Document Type: Article

References (19)

1. Arbuck SG, Christian MC, Fisherman JS, et al: Clinical development of Taxol. NCI Monogr 15:11-24, 1993
2. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
3. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
4. Seidman A, Crown J, Reichman B, et al: Lack of clinical cross-resistance of Taxol (T) with anthracycline (A) in the treatment of metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 12:53A, 1993 (abstr)
5. Holmes FA, Valero V, Theriault RL, et al: Phase II trial of Taxol in metastatic breast cancer refractory to multiple prior treatments. Proc Am Soc Clin Oncol 12:178A, 1993 (abstr)
6. McGuire WP, Hoskins WJ, Brady MF, et al: A phase III trial comparing cisplatin/Cytoxan and cisplatin/Taxol in advanced ovarian cancer. Proc Am Soc Clin Oncol 12:808A, 1993 (abstr)
7. Gelmon KA, O'Reilly S, Plenderleith IH, et al: Bi-weekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 12:87A, 1993 (abstr)
8. Wasserheit C, Alter R, Speyer J, et al: Phase II trial of paclitaxel and cisplatin (DDP) in women with metastatic breast cancer. Proc Am Soc Clin Oncol 12:204A, 1993 (abstr)
9. Holmes FA, Frye D, Valero V, et al: Phase I study of Taxol (T) and doxorubicin (D) with G-CSF in patients (PT) without prior chemotherapy (CT) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 11:66A, 1992 (abstr)
10. Holmes FA, Newman RA, Madden T, et al: Schedule dependent pharmacokinetics (PK) in a phase I trial of Taxol (T) and doxorubicin (D) as initial chemotherapy for metastatic breast cancer. Ann Oncol 5:489A, 1994 (suppl 5, abstr)
11. Sledge GW, Robert N, Goldstein LJ, et al: Phase I trial of Adriamycin (A) + Taxol (T) in metastatic breast cancer (MBC). Eur J Cancer 29:A421, 1993 (suppl 6, abstr)
12. Fisherman JS, McCabe M, Noone M, et al: Phase I study of Taxol, doxorubicin plus granulocyte-colony stimulating factor in patients with metastatic breast cancer. NCI Monogr 15:189-194, 1993
13. Rowinsky EK, Gilbert M, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
14. Cook JA, Fisher J, Teague D, et al: Sequence dependence of paclitaxel combined with cisplatin or alkylators in human cancer cells. Proc Am Assoc Cancer Res 35:1975A, 1994 (abstr)
15. Longnecker SM, Donehower RC, Cates AE, et al: High-performance liquid chromatographic assay for Taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53-59, 1987
16. Chen T-L, Passos-Coelho J-L, Noe DA, et al: Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplant. Cancer Res 55:810-816, 1995
17. LeBlanc GA, Sundseth SS, Weber GF, et al: Platinum anticancer drugs modulate p-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res 5:540-547, 1992
18. Holmes FA, Valero V, Walters RS, et al: The M.D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. NCI Monogr 15:161-170, 1993
19. Rowinsky EK, Citardi MJ, Noe DA, et al: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents Taxol and vincristine J Cancer Res Clin Oncol 119:727-733, 1993